pembrolizumab
merck
['melanoma']
2 year dmfs benefit for stage iib/c #melanoma patients treated with adjuvant #immunotherapy at #asco22 . on our way to curing more patients at the early stages 
Medical oncologist, @lemelbaum institute for immuno-oncology. Treating patients with #Melanoma, interested in #Immunotherapy and clinical trials